Article
Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.
Tuberculosis (Edinburgh, Scotland) - 1 Sept 2022
Masiphephethu Maano V, Sariko Margaretha, Walongo Thomas, Maro Athanasia, Mduma Dorcus, Gratz Jean, Alshaer Mohammad, Peloquin Charles A, Mduma Estomih, Mpagama Stellah G, Thomas Tania, Houpt Eric R, Traore Afsatou, Bessong Pascal, Heysell Scott K, Operario Darwin J
Abstract excerpt
Despite updated recommendations for weight-based isoniazid dosing in children with drug-susceptible tuberculosis (TB) and higher dose isoniazid in regimens for adults with drug-resistant TB, individual pharmacokinetic variability can lead to sub-target isoniazid exposure. Host pharmacogenetics and isoniazid exposure remain understudied, especially in the East African population. We therefore employed a real-time...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.